BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA). The investigation concerns possible violations of federal securities laws and focuses on the Company’s operations and prospects.
STAAR, together with its subsidiaries, designs, develops, manufactures and sells implantable lenses for the eye and delivery systems to deliver lenses into the eye. The investigation is related to a U.S. Food and Drug Administration Warning Letter, dated May 21, 2014, concerning an inspection of STAAR’s Monrovia, California, facility from February 10, 2014 to March 21, 2014. The FDA letter noted several regulatory violations at the facility and stated that, among other things, “the methods used in, or the facilities or controls used for” manufacture, packing, storage or installation of the Company’s implantable lenses are “not in conformity with the current good manufacturing practice requirements.” The FDA further advised STAAR that “failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.”
If you purchased STAAR securities, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at 215-638-4847, Toll-Free at 888-638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.